These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30346496)

  • 21. Preventing adverse events of chemotherapy by educating patients about the nocebo effect (RENNO study) - study protocol of a randomized controlled trial with gastrointestinal cancer patients.
    Quidde J; Pan Y; Salm M; Hendi A; Nilsson S; Oechsle K; Stein A; Nestoriuc Y
    BMC Cancer; 2018 Sep; 18(1):916. PubMed ID: 30249191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. People's Understanding of Verbal Risk Descriptors in Patient Information Leaflets: A Cross-Sectional National Survey of 18- to 65-Year-Olds in England.
    Webster RK; Weinman J; Rubin GJ
    Drug Saf; 2017 Aug; 40(8):743-754. PubMed ID: 28497250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of patient information leaflets provided by a district general hospital by the Flesch and Flesch-Kincaid method.
    Williamson JM; Martin AG
    Int J Clin Pract; 2010 Dec; 64(13):1824-31. PubMed ID: 21070533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Consumer study on the use of patient information leaflets].
    Leemans L; Heylen N; Quanten A; Deferme S
    J Pharm Belg; 2011 Dec; (4):109-16. PubMed ID: 22299237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Written medicines information for South African HIV/AIDS patients: does it enhance understanding of co-trimoxazole therapy?
    Mansoor L; Dowse R
    Health Educ Res; 2007 Feb; 22(1):37-48. PubMed ID: 16763073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Positive Mood Induction for Reducing the Formation of Nocebo Effects from Side Effect Information.
    Geers AL; Close S; Caplandies FC; Vase L
    Ann Behav Med; 2019 Oct; 53(11):999-1008. PubMed ID: 30855691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When describing harms and benefits to potential trial participants, participant information leaflets are inadequate.
    Cuddihy L; Howick J; Murphy E; Shiely F
    Trials; 2024 May; 25(1):292. PubMed ID: 38693579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The development of patient information leaflets incorporating patient diversity considerations: Varicocele embolisation and fluoroscopy guided joint injection examinations.
    Vassallo T; Mizzi A; Depasquale R; Maher M; Rainford L
    Radiography (Lond); 2018 Oct; 24 Suppl 1():S20-S27. PubMed ID: 30166004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative importance of informational items in participant information leaflets for trials: a Q-methodology approach.
    Innes K; Cotton S; Campbell MK; Elliott J; Gillies K
    BMJ Open; 2018 Sep; 8(9):e023303. PubMed ID: 30185580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the Readability of Dermatological Postoperative Patient Information Leaflets Across England.
    Hunt WT; McGrath EJ
    Dermatol Surg; 2016 Jun; 42(6):757-63. PubMed ID: 27176870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Providing information on metered dose inhaler technique: is multimedia as effective as print?
    Savage I; Goodyer L
    Fam Pract; 2003 Oct; 20(5):552-7. PubMed ID: 14507797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
    Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
    JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seeing is believing: Impact of social modeling on placebo and nocebo responding.
    Faasse K; Grey A; Jordan R; Garland S; Petrie KJ
    Health Psychol; 2015 Aug; 34(8):880-5. PubMed ID: 25545042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults.
    Antonijoan R; García-Gea C; Puntes M; Pérez J; Esbrí R; Serra C; Fortea J; Barbanoj MJ
    Clin Ther; 2007 May; 29(5):814-822. PubMed ID: 17697901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABOP, the automatic patient information leaflet optimizer: evaluation of a tool in development.
    Franck MC; Foulon V; Van Vaerenbergh L
    Patient Educ Couns; 2011 Jun; 83(3):411-6. PubMed ID: 21621946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Framing of health information messages.
    Akl EA; Oxman AD; Herrin J; Vist GE; Terrenato I; Sperati F; Costiniuk C; Blank D; Schünemann H
    Cochrane Database Syst Rev; 2011 Dec; (12):CD006777. PubMed ID: 22161408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. You Can't Always Get What You Want: The Influence of Choice on Nocebo and Placebo Responding.
    Bartley H; Faasse K; Horne R; Petrie KJ
    Ann Behav Med; 2016 Jun; 50(3):445-51. PubMed ID: 26779715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review of factors that contribute to nocebo effects.
    Webster RK; Weinman J; Rubin GJ
    Health Psychol; 2016 Dec; 35(12):1334-1355. PubMed ID: 27657801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The quality of written information for parents regarding the management of a febrile convulsion: a randomized controlled trial.
    Paul F; Jones MC; Hendry C; Adair PM
    J Clin Nurs; 2007 Dec; 16(12):2308-22. PubMed ID: 18036121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreasing the Burden of Side Effects Through Positive Message Framing: an Experimental Proof-of-Concept Study.
    Wilhelm M; Rief W; Doering BK
    Int J Behav Med; 2018 Aug; 25(4):381-389. PubMed ID: 29785686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.